{"id":"dabigatran","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Gastrointestinal adverse reactions","drugRate":"","severity":"common","organSystem":""},{"effect":"Bleeding","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute hemorrhage","Acute nephropathy","Anemia","Blood coagulation disorder","Cerebral hemorrhage"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Major bleeding","drugRate":"","severity":"serious"},{"effect":"Intracranial hemorrhage","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal hemorrhage","drugRate":"","severity":"serious"},{"effect":"Thrombotic events","drugRate":"","severity":"serious"},{"effect":"Thromboembolic events","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT01812200","NCT02935855","NCT02044367","NCT00846807","NCT02170844","NCT02120560","NCT01962545","NCT01225822","NCT06449469","NCT02170922","NCT01511939","NCT05006287","NCT04695106","NCT03187197","NCT01896297","NCT06887270","NCT04412291","NCT04498741","NCT02170597","NCT03520868","NCT05959447","NCT05966740","NCT06057467","NCT02170623","NCT02309970","NCT05990894","NCT02171533","NCT02921126","NCT02171507","NCT03327350","NCT03183843","NCT04056143","NCT04459585","NCT01118299","NCT02103101","NCT06058130","NCT01379300","NCT02171481","NCT04394234","NCT02864758","NCT02568397","NCT04518735","NCT03947385","NCT02170740","NCT02171468","NCT02631057","NCT02723981","NCT02504177","NCT02946931","NCT05825573"],"aliases":["Pradaxa"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.8082/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,025","description":"DABIGATRAN ETEXILATE 150 MG CP","retrievedDate":"2026-04-07"}],"allNames":"pradaxa","offLabel":[],"timeline":[],"aiSummary":"Dabigatran (Pradaxa) was the first DOAC, developed by Boehringer Ingelheim and approved in 2010. It offers anticoagulation without INR monitoring and has a specific reversal agent (Praxbind). Available generically in some markets.","brandName":"Pradaxa","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","novelty":"","modality":"Small molecule","drugClass":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","explanation":"Dabigatran was the first direct oral anticoagulant (DOAC) approved, directly inhibiting thrombin without the need for INR monitoring required by warfarin. The RE-LY trial showed non-inferiority to warfarin for stroke prevention in AF. It has a specific reversal agent (idarucizumab/Praxbind) for emergency situations.","oneSentence":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.","technicalDetail":""},"commercial":{"revenueYear":2024,"annualRevenue":1200,"revenueSource":"Verified: Boehringer AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[],"biosimilars":[],"companyName":"Generic (originally Boehringer Ingelheim)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"dabigatran etexilate","indications":{"approved":[{"name":"Deep vein thrombosis","diseaseId":"deep-vein-thrombosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","diseaseId":"prevention-of-thromboembolism-with-chronic-atrial-fibrillation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of deep vein thrombosis","diseaseId":"prevention-of-deep-vein-thrombosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of stroke","diseaseId":"prevention-of-stroke","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of systemic embolism","diseaseId":"prevention-of-systemic-embolism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary embolism","diseaseId":"pulmonary-embolism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01812200","phase":"Phase 4","title":"A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dab","status":"COMPLETED","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":60,"indication":"Atrial Fibrillation, Acute Coronary Syndrome","completionDate":"2013-07"},{"nctId":"NCT02935855","phase":"Phase 4","title":"Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non","status":"COMPLETED","sponsor":"University of Pavia","isPivotal":false,"enrollment":300,"indication":"Diabetes","completionDate":"2019-09"},{"nctId":"NCT02044367","phase":"Phase 1","title":"Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pell","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":54,"indication":"Healthy","completionDate":"2014-04"},{"nctId":"NCT00846807","phase":"N/A","title":"Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":5476,"indication":"Arthroplasty, Replacement, Thromboembolism","completionDate":""},{"nctId":"NCT02170844","phase":"Phase 1","title":"Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of 50, 150 and 350 mg BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin. Double-blind at Each D","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":""},{"nctId":"NCT02120560","phase":"Phase 4","title":"Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance","status":"WITHDRAWN","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":0,"indication":"Atrial Fibrillation, Cerebrothromboembolus","completionDate":"2015-07"},{"nctId":"NCT01962545","phase":"Phase 4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","isPivotal":false,"enrollment":690,"indication":"Atrial Fibrillation, Coronary Artery Disease","completionDate":"2018-05-18"},{"nctId":"NCT01225822","phase":"Phase 2","title":"BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":1973,"indication":"Venous Thromboembolism","completionDate":""},{"nctId":"NCT06449469","phase":"NA","title":"Prospective Study on the Impact of Different Anti-thrombotic Therapies on Subclinical Leaflet Thickening and Its Temporal Dynamics in Transcatheter Bioprosthetic Aortic Valves (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","isPivotal":false,"enrollment":352,"indication":"Aortic Valve Stenosis, Cardiovascular Diseases","completionDate":"2030-04-01"},{"nctId":"NCT02170922","phase":"Phase 1","title":"Relative Bioavailability of 200 mg Film Coated Tablets of BIBR 1048 MS With or Without Food Compared to 200 mg Solution of BIBR 1048 MS Given as Single Oral Administrations to Healthy Subjects. A 3-wa","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":6,"indication":"Healthy","completionDate":""},{"nctId":"NCT01511939","phase":"Phase 3","title":"Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, INR and Platelet Function) in Patients With Moderate to Severe Osteoarthr","status":"COMPLETED","sponsor":"Nathan Wei, MD, FACP, FACR:","isPivotal":true,"enrollment":22,"indication":"Osteoarthritis of the Knee, Coagulopathy","completionDate":"2013-05"},{"nctId":"NCT05006287","phase":"Phase 2","title":"A Randomized Trial of the Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery: a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","isPivotal":false,"enrollment":100,"indication":"Atrial Fibrillation","completionDate":"2024-05-30"},{"nctId":"NCT04695106","phase":"Phase 4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)","status":"UNKNOWN","sponsor":"Medical University of Gdansk","isPivotal":false,"enrollment":2230,"indication":"Atrial Fibrillation, Antithrombotic Therapy","completionDate":"2026-03-31"},{"nctId":"NCT03187197","phase":"N/A","title":"Patients Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":1315,"indication":"Atrial Fibrillation","completionDate":"2019-01-11"},{"nctId":"NCT01896297","phase":"Phase 4","title":"A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg B","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":63,"indication":"Atrial Fibrillation","completionDate":"2015-10"},{"nctId":"NCT06887270","phase":"NA","title":"Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation (VENOCAT) Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","isPivotal":false,"enrollment":10,"indication":"Anticoagulant-induced Bleeding, Direct Oral Anticoagulant","completionDate":"2027-09"},{"nctId":"NCT04412291","phase":"Phase 2","title":"A Multi-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatmen","status":"UNKNOWN","sponsor":"Karolinska University Hospital","isPivotal":false,"enrollment":120,"indication":"Covid-19","completionDate":"2021-06"},{"nctId":"NCT04498741","phase":"Phase 1","title":"A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjec","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","isPivotal":false,"enrollment":89,"indication":"RSV Infection","completionDate":"2021-06-01"},{"nctId":"NCT02170597","phase":"Phase 1","title":"Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Capsule Relative to a Gelatine Capsule, and Bioavailability of the HPMC Capsule Under the I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":12,"indication":"Healthy","completionDate":""},{"nctId":"NCT03520868","phase":"N/A","title":"Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs","status":"COMPLETED","sponsor":"Steward St. Elizabeth's Medical Center of Boston, Inc.","isPivotal":false,"enrollment":60,"indication":"Atrial Fibrillation","completionDate":"2020-03-30"},{"nctId":"NCT05959447","phase":"Phase 1","title":"A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","isPivotal":false,"enrollment":45,"indication":"Cough, Healthy","completionDate":"2023-10-13"},{"nctId":"NCT05966740","phase":"N/A","title":"Safety and Effectiveness of Pradaxa Oral Pellet Formulation for Treatment of Acute Venous Thromboembolic Events (VTE) and/or for Risk Reduction of Recurrence of VTE in Pediatric Patients Aged 3 Months","status":"TERMINATED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":6,"indication":"Venous Thromboembolism","completionDate":"2025-04-28"},{"nctId":"NCT06057467","phase":"NA","title":"Early Versus Late Initiation of Anticoagulation in Mild-to-moderate Acute Ischemic Stroke Patients With Non-valvular Atrial Fibrillation","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":2351,"indication":"Acute Ischemic Stroke, Atrial Fibrillation","completionDate":"2026-01-01"},{"nctId":"NCT02170623","phase":"Phase 1","title":"Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":12,"indication":"Healthy","completionDate":""},{"nctId":"NCT02309970","phase":"N/A","title":"","status":"UNKNOWN","sponsor":"Rabin Medical Center","isPivotal":false,"enrollment":90,"indication":"Ischemic Stroke","completionDate":"2016-03"},{"nctId":"NCT05990894","phase":"N/A","title":"Efficacy and Safety of Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","isPivotal":false,"enrollment":170,"indication":"Cerebral Venous Thrombosis","completionDate":"2024-07-31"},{"nctId":"NCT02171533","phase":"Phase 1","title":"Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequ","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":""},{"nctId":"NCT02921126","phase":"N/A","title":"Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":9914,"indication":"Anticoagulation","completionDate":"2018-08-02"},{"nctId":"NCT02171507","phase":"Phase 1","title":"Relative Bioavailability of Dabigatran and Diclofenac After 150 mg b.i.d. Dabigatran Etexilate and Diclofenac at 50 mg Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healt","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":""},{"nctId":"NCT03327350","phase":"N/A","title":"The WASPS Trails:WATCHMAN for Second Prevention of Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":400,"indication":"Atrial Fibrillation, Stroke","completionDate":"2020-11"},{"nctId":"NCT03183843","phase":"Phase 4","title":"The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement","status":"UNKNOWN","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","isPivotal":false,"enrollment":40,"indication":"Mitral Valve Stenosis and Insufficiency, Atrial Fibrillation","completionDate":"2018-12-01"},{"nctId":"NCT04056143","phase":"N/A","title":"Development of Precision Medicine Platform for Pharmacogenomics of Novel Oral Anticoagulants (NOACs)","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","isPivotal":false,"enrollment":500,"indication":"Anticoagulant Adverse Reaction","completionDate":"2022-12-31"},{"nctId":"NCT04459585","phase":"EARLY/Phase 1","title":"A Phase 1, Open-Label, Fixed Sequence Drug Interaction Study to Evaluate the Potential Intestinal Inhibitory Effect of Quizartinib on the Pharmacokinetics of a Pgp Substrate Dabigatran Etexilate in He","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","isPivotal":false,"enrollment":20,"indication":"Healthy Subjects, Drug-drug Interaction","completionDate":"2020-10-20"},{"nctId":"NCT01118299","phase":"NA","title":"Amplatzer Cardiac Plug Clinical Trial","status":"COMPLETED","sponsor":"Abbott Medical Devices","isPivotal":false,"enrollment":97,"indication":"Atrial Fibrillation, Ischemic Stroke","completionDate":"2018-12-06"},{"nctId":"NCT02103101","phase":"NA","title":"Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","isPivotal":false,"enrollment":68,"indication":"Anticoagulants, Thromboembolism","completionDate":"2017-10-31"},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for Acute Ischemic Stroke Patients Witn Concomitant Non-valvular Atrial Fibrillation and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":2171,"indication":"Acute Ischemic Stroke, Atrial Fibrillation","completionDate":"2026-01-01"},{"nctId":"NCT01379300","phase":"Phase 1","title":"A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":42,"indication":"Thrombosis","completionDate":"2011-12"},{"nctId":"NCT02171481","phase":"Phase 1","title":"Bioequivalence of Two Different Polymorphs of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design i","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":66,"indication":"Healthy","completionDate":""},{"nctId":"NCT04394234","phase":"N/A","title":"Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across 4 US Observational Databases","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":961985,"indication":"Uterine Hemorrhage","completionDate":"2020-06-01"},{"nctId":"NCT02864758","phase":"N/A","title":"Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in Daily Clinical Practice - A French Cohort Within the Nationwide Claims and Hospital Database","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":99999,"indication":"Atrial Fibrillation","completionDate":"2018-09-30"},{"nctId":"NCT02568397","phase":"Phase 1","title":"Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":60,"indication":"Healthy","completionDate":"2016-01-31"},{"nctId":"NCT04518735","phase":"N/A","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","isPivotal":false,"enrollment":1707,"indication":"Covid19","completionDate":"2020-06-30"},{"nctId":"NCT03947385","phase":"Phase 1","title":"A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","status":"RECRUITING","sponsor":"IDEAYA Biosciences","isPivotal":false,"enrollment":336,"indication":"Metastatic Uveal Melanoma, Cutaneous Melanoma","completionDate":"2027-06-15"},{"nctId":"NCT02170740","phase":"Phase 1","title":"Bioavailability of BIBR 953 ZW After Multiple Oral Doses of 50 and 200 mg BIBR 1048 MS Film-coated Tablet Administered BIDfor 3 Days or 200 mg BIBR 1048 MS With and Without Pre-treatment With Pantopra","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":""},{"nctId":"NCT02171468","phase":"Phase 1","title":"Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label S","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":""},{"nctId":"NCT02631057","phase":"N/A","title":"Comparison of the Length of Stay in Patients Hospitalized and Initiated With Dabigatran or Warfarin for a Concomitant Non-Valvular Atrial Fibrillation in Real-world Japanese Therapeutic Practice (SHOR","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":4313,"indication":"Atrial Fibrillation","completionDate":"2016-09-07"},{"nctId":"NCT02723981","phase":"Phase 4","title":"Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Singl","status":"WITHDRAWN","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","isPivotal":false,"enrollment":0,"indication":"Stable Angina, Unstable Angina","completionDate":"2018-12"},{"nctId":"NCT02504177","phase":"NA","title":"","status":"UNKNOWN","sponsor":"Yonsei University","isPivotal":false,"enrollment":433,"indication":"Atrial Fibrillation","completionDate":"2019-06"},{"nctId":"NCT02946931","phase":"N/A","title":"The Drug Use-results Survey (All-Case Surveillance) on Prizbind® for Intravenous Solution 2.5 g in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":1402,"indication":"Hemorrhage","completionDate":"2020-11-03"},{"nctId":"NCT05825573","phase":"Phase 3","title":"Anticoagulant Regimens Given to Achieve Thrombus Regression and Reduce Clinical Outcomes Among Patients With Non Device-related Intra-cardiac Thrombus: a Randomized Assessment Under Direct Oral Antico","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","isPivotal":true,"enrollment":340,"indication":"Intracardiac Thrombus, STEMI","completionDate":"2026-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Twice daily","formulation":"Capsule"},"crossReferences":{"unii":"SC7NUW5IIT","rxcui":"1037042","splId":"4f8d4596-bc1a-48a1-8f6a-caf816a2037f","chemblId":"CHEMBL539697","pubchemSID":"99443249"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"_revenueScrapedAt":"2026-04-08 13:58:17.1368+00","biosimilarFilings":[],"firstApprovalDate":"2010-10-19","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-12-15T00:00:00.000Z","mah":"APOTEX","brand_name_local":null,"application_number":"ANDA208070"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-09-11T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA208040"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-28T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA208048"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-02-03T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"ANDA208067"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-14T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA208039"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"1025.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1025.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1025.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1025.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1025.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":9,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}